文献速递脑血管病外科

符合ARUBA临床试验入组标准的患者介入治疗结局:系统评价与Meta分析

Interventional outcomes for patients eligible for entry into the ARUBA clinical trial: a systematic review and meta-analysis.
PubMed 文献 · J Neurosurg · 2021-11-05

该Meta分析汇总13项符合ARUBA入组标准(年龄≥18岁、无AVM出血史、未接受过干预)的介入治疗研究共1909例患者,主要结局(死亡或症状性卒中)发生率为11.2%(合并值11%,95%CI 8%-13%),AVM闭塞率72.7%(合并值78%,95%CI 70%-85%),出血率8.4%(合并值8%,95%CI 6%-11%),不良结局9.9%(合并值10%,95%CI 7%-13%),死亡率3.5%(合并值2%,95%CI 1%-4%)。作者结论认为对适当选择的患者介入治疗可获得可接受的结局。

要点

  • 符合ARUBA标准的患者介入治疗后主要结局(死亡或症状性卒中)合并发生率为11%(95%CI 8%-13%)。
  • AVM闭塞合并率为78%(95%CI 70%-85%),出血合并率8%(95%CI 6%-11%)。
  • 年化主要结局风险为2.05/100患者年(95%CI 1.31-2.94),年化出血风险为1.41/100患者年(95%CI 0.83-2.13)。

核心结论

  • 对未破裂AVM的介入治疗在适当选择的患者中可获得可接受的结局。
  • 介入后出血风险与未破裂AVM自然病史相比表现有利。
  • 纳入研究为回顾性且治疗与AVM特征存在差异,限制了数据的普遍性。
  • 未来来自前瞻性登记的研究可能明确患者、瘤巢和介入选择标准,以优化未破裂AVM患者的管理。

研究设计与样本

  • 系统检索PubMed、Web of Science和Google Scholar中采用与ARUBA相同入组标准(年龄≥18岁、无AVM出血史、无既往干预)的AVM介入治疗研究。
  • 共纳入13项研究,合计1909例患者。
  • 主要结局为死亡或症状性卒中,次要结局包括AVM闭塞、出血、死亡和不良结局(末次随访时改良Rankin量表评分≥2)。
  • 采用纽卡斯尔-渥太华量表进行偏倚评估,结果以合并比例合成。

主要发现

  • 主要结局发生于11.2%的患者(合并值11%,95%CI 8%-13%)。
  • AVM闭塞率为72.7%(合并值78%,95%CI 70%-85%)。
  • 出血率为8.4%(合并值8%,95%CI 6%-11%)。
  • 不良结局率为9.9%(合并值10%,95%CI 7%-13%)。
  • 死亡率为3.5%(合并值2%,95%CI 1%-4%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 纳入的研究为回顾性研究。
  • 纳入研究的治疗和AVM特征存在差异,限制了数据的普遍性。
  • 未来需要来自前瞻性登记的研究来明确患者、瘤巢和介入选择标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) suggested that medical management afforded outcomes superior to those following intervention for unruptured arteriovenous malformations (AVMs), but its findings have been controversial. Subsequent studies of AVMs that would have met the eligibility requirements of ARUBA have supported intervention for the management of some cases. The present meta-analysis was conducted with the object of summarizing interventional outcomes for ARUBA-eligible patients reported in the literature. METHODS: A systematic literature search (PubMed, Web of Science, Google Scholar) for AVM intervention studies that used inclusion criteria identical to those of ARUBA (age ≥ 18 years, no history of AVM hemorrhage, no prior intervention) was performed. The primary outcome was death or symptomatic stroke. Secondary outcomes included AVM obliteration, hemorrhage, death, and poor outcome (modified Rankin Scale score ≥ 2 at final follow-up). Bias assessment was performed with the Newcastle-Ottawa Scale, and the results were synthesized as pooled proportions. RESULTS: Of the 343 articles identified through database searches, 13 studies met the inclusion criteria, yielding an overall study cohort of 1909 patients. The primary outcome occurred in 11.2% of patients (pooled = 11%, 95% CI 8%-13%). The rates of AVM obliteration, hemorrhage, poor outcome, and death were 72.7% (pooled = 78%, 95% CI 70%-85%), 8.4% (pooled = 8%, 95% CI 6%-11%), 9.9% (pooled = 10%, 95% CI 7%-13%), and 3.5% (pooled = 2%, 95% CI 1%-4%), respectively. Annualized primary outcome and hemorrhage risks were 1.85 (pooled = 2.05, 95% CI 1.31-2.94) and 1.34 (pooled = 1.41, 95% CI 0.83-2.13) per 100 patient-years, respectively. CONCLUSIONS: Intervention for unruptured AVMs affords acceptable outcomes for appropriately selected patients. The risk of hemorrhage following intervention compared favorably to the natural history of unruptured AVMs. The included studies were retrospective and varied in treatment and AVM characteristics, thereby limiting the generalizability of their data. Future studies from prospective registries may clarify patient, nidus, and intervention selection criteria that will refine the challenging management of patients with unruptured AVMs.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Snyder MH, Chen CJ, Farzad F, et al. Interventional outcomes for patients eligible for entry into the ARUBA clinical trial: a systematic review and meta-analysis. J Neurosurg. 2021. PMID: 34740184. doi:10.3171/2021.7.JNS211186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。